STAT Feb 10
Hims faces mounting regulatory pressure:
Today's biotech news covers ARPA-H cutting staff, Novo Nordisk's lawsuit against Hims ...
statnews.com/2026/02/09/biotech-news-novo-nordisk-sues-hims-patent-lawsuit/
Paid articlePaywallStory Details
| Last Updated | |
| Total Articles | 2 |
Main Topics
Similar to This
Previous
Hims & Hers Q1 2026 earnings: net loss, weak guidance: The telehealth company posted a net loss of $92 million in the first quarter as its shift away from ...
qz.com/hims-hers-net-loss-weight-loss-drug-pivot-051226
STAT May 13
Hims’ sales miss as telehealth competition grows: Today's biotech news covers Bristol's partnership with Hengrui Pharma, Viiv loses HIV treatment case ...
statnews.com/2026/05/12/biotech-news-hims-sales-miss-as-telehealth-competition-grows/
Paid articlePaywall
Barron's Mar 10
Wall Street Gets Less Bearish on Hims & Hers After Novo Nordisk Truce. Stock Gains Could Still Be Limited.
barrons.com/articles/wall-street-gets-less-bearish-on-hims-hers-aaeb4947
Paid articlePaywall
Novo Nordisk, Hims Team Up to Sell Wegovy Online, Stunning Wall Street: The unexpected partnership comes one month after the Danish drugmaker decried Hims' plan ...
inc.com/kevin-haynes/novo-nordisk-hims-team-up-to-sell-wegovy-online-stunning-wall-street/91313670
STAT Feb 24
Novo reports ‘triple G’ obesity drug study results: Today's biotech news includes Novo Nordisk's "triple G" obesity drug study results ...
statnews.com/2026/02/24/biotech-news-novo-nordisk-triple-g-obesity-results/
Paid articlePaywall
ANALYSIS-US could take action, including fines, against Hims after brief Wegovy copy launch
postandcourier.com/us-action-fines-hims-wegovy-copy/article_9f164062-887f-4d5f-9544-7bf121c5111e.html
STAT Feb 20
Hims’ Super Bowl fallout, and the FDA reverses course: Was Hims' Super Bowl ad the final straw for regulators? STAT's Katie Palmer joins the podcast ...
statnews.com/2026/02/19/hims-super-bowl-ad-moderna-fda-readout-loud/
STAT Feb 12
The unusual Prasad missive in the FDA’s rejection of the Moderna flu shot application
statnews.com/2026/02/11/biotech-news-prasad-missive-fda-moderna-flu-shot-rejection/
Paid articlePaywall
Novo Nordisk sues Hims & Hers over copycat versions of Wegovy drugs; Hims stock falls 18%
cnbc.com/2026/02/09/novo-nordisk-sues-hims-hers-compounded-obesity-drugs.html
The fight over copycat weight-loss drugs escalates: The outcome will decide if cheaper versions of the treatments not evaluated by the FDA remain widely ...
axios.com/2026/02/11/weight-loss-drugs-glp1-big-pharma-trump
Novo Nordisk surges as Hims pulls $49 weight loss pill under FDA pressure: Novo Nordisk's shares jumped more than 8% on Monday after telehealth firm Hims & Hers ...
reuters.com/sustainability/boards-policy-regulation/novo-nordisk-shares-rise-hims-abandons-49-weight-loss-pill-2026-02-09/
STAT Feb 07
Hims & Hers will stop selling compounded version of Novo’s obesity pill: The decision comes after health officials called for an investigation into the company.
statnews.com/2026/02/07/hims-wont-sell-compounded-obesity-pill-novo/
Paid articlePaywall
Hims & Hers abandons copycat weight-loss drug in face of FDA probe: Novo Nordisk had accused the telehealth company of breaching its patent on Wegovy
ft.com/content/3d4f88e9-33aa-4e1d-81af-ae6954598d63
Paid articlePaywall
Cheap, copycat Ozempic was supposed to go away. It's still everywhere.: Online pharmacies are using a loophole to continue selling cheap weight loss drugs that ...
businessinsider.com/compounded-ozempic-semaglutide-hims-hers-eli-lilly-novo-nordisk-fda-2025-9
CVS Caremark drops coverage of popular weight loss drug: Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly ...
foxbusiness.com/lifestyle/cvs-caremark-drops-coverage-popular-weight-loss-drug
Novo Nordisk says WeightWatchers will sell Wegovy, announces $299 price: Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its ...
reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-ties-up-with-weightwatchers-sell-wegovy-2025-06-26/
Key FactsNovo Nordisk Teams Up with WeightWatchers for Wegovy Sales
Jun 27, 2025 · Reading time: ~45 sec.
Summary created with AI assistance · Source: reuters.com
Summary created with AI assistance · Source: reuters.com
- Novo Nordisk will collaborate with WeightWatchers from July to distribute the weight-loss drug Wegovy.
- A month’s supply of Wegovy will be available for $299 via Novocare pharmacy and other telehealth platforms through July 31.
- WeightWatchers ceased offering compounded semaglutide versions after exiting bankruptcy protection.
- Novo Nordisk continues discussions with other partners while maintaining agreements with Ro and LifeMD.
We will continue to pursue and build on agreements with companies that share our values and refine initiatives that help improve access to our FDA-approved medicines for patients.— Dave Moore, an executive vice president at Novo Nordisk, discussing the partnership with WeightWatchers.
Novo Nordisk ends collaboration with Hims & Hers for discounted weight loss meds: Novo Nordisk and Hims & Hers just announced a partnership in April.
goodmorningamerica.com/wellness/story/novo-nordisk-ends-collaboration-hims-discounted-weight-loss-123122046
Novo Nordisk terminates deal with Hims over compounded GLP-1s: Hims & Hers’ stock fell 30% in early trading Monday after Novo announced it was terminating their ...
modernhealthcare.com/health-tech/digital-healthmh-novo-nordisk-hims-hers-glp-1s/
Hims to cut 4% of workforce amid ban on weight-loss drug copies: Telehealth platform Hims & Hers said on Friday it will cut 68 employees, or about 4% of its ...
reuters.com/business/healthcare-pharmaceuticals/hims-cut-4-workforce-amid-ban-weight-loss-drug-copies-2025-05-30/
Hims & Hers stock jumps on Novo Nordisk GLP-1 partnership: Novo Nordisk launched access to its popular weight loss GLP-1 drug, Wegovy, through multiple ...
finance.yahoo.com/news/hims--hers-stock-jumps-on-novo-nordisk-glp-1-partnership-141811461.html
Next